Noxopharm CEO Resigns After 4-Year Tenure
Key points
- Resignation of CEO and Managing Director Dr. Gisela Mautner
- Mautner joined Noxopharm in 2019 as Chief Medical Officer, became CEO in 2022
- Noxopharm Chairman thanks Mautner for her hard work and dedication
Full summary
Noxopharm Limited (ASX:NOX), a clinical-stage Australian biotech company, has announced the resignation of CEO and Managing Director Dr. Gisela Mautner. Dr. Mautner joined Noxopharm in 2019 as Chief Medical Officer and became CEO and MD in early 2022. Noxopharm Chairman Fred Bart expressed gratitude for Dr. Mautner's hard work and dedication over the past four years, including overseeing an important change in strategic direction, and wished her all the best. The company expects to announce a successor in the very near future. Noxopharm is a biotech company focused on discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.
Summary generated by a large language model. Please interpret with care.